FORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET No.	SERIAL NO.		
6102-000048/US/NP	10/593,964		
APPLICANT			
Scheller, D. , et al.			
FILING DATE	GROUP		
September 22, 2006	1617		

ATENT DOCUM	NENIO				
Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
	2003/0026830	Feb 6, 2003	Lautertback, et al.	424/449	May 7, 2002
	2003/0027793	Feb 6, 2003	Lautertback, et al.	514/63	May 7, 2002
	2003/0166709	Sep 4, 2003	Rimpler, et al.	514/447	Feb 11, 2003
	2004/0034083	Feb 19, 2004	Stephenson et al.	514/406	Apr 14, 2003
	2004/0048779	Mar 11, 2004	Schollmayer	514/2	May 2, 2003
	2004/0081683	Apr 29, 2004	Schacht, et al.	424/449	Jul 28, 2003
	2004/0137045	Jul 15, 2004	Breitenbach, et al.	424/449	Feb 6, 2004
	2004/0209861	Oct 21, 2004	Benavides, et al.	514/210.01	Feb 25, 2004
	2005/0032843	Feb 10, 2005	Pieper, et al.	514/338	Sep 7, 2004
	2005/0033065	Feb 10, 2005	Mueller, et al.	549/74	Sep 7, 2004
	2005/0079206	Apr 14, 2005	Schacht, et al.	424/449	Jul 22, 2003
	2005/0175678	Aug 11, 2005	Breitenbach	424/448	Dec 6, 2004
	2005/0260254	Nov 24, 2005	Breitenbach, et al.	424/449	Jan 28, 2005
	2006/0263419	Nov 23, 2006	Wolff	424/448	Sep 29, 2005
	2007/0072917	Mar 29, 2007	Scheller, et al.	514/357	Jan 25, 2006
	2007/0093546	Apr 26, 2007	Scheller, et al.	514/447	Jan 25, 2006
	2007/0191308	Aug 16, 2007	Kramer	514/60	Aug 15, 2005
	2007/0197480	Aug 23, 2007	Scheller, et al.	514/114	Feb 6, 2007
	2008/0008748	Jan 10, 2008	Beyreuther, et al.	424/449	Jun 19, 2007
	2008/0138389	Jun 12, 2008	Muller, et al.	424/448	Oct 31, 2007
	2008/0146622	Jun 19, 2008	Scheller, et al.	514/357	Mar 12, 2007
	2008/0274061	Nov 6, 2008	Schollmayer, et al.	424/45	May 2, 2008
	2009/0143460	Jun 4, 2009	Wolff, et al.	514/438	Nov 26, 2008
	5,177,112	Jan 5, 1993	Horn	514/65	Sep 10, 1991
	5,382,596	Jan 17, 1995	Sleevi, et al.	514/459	Aug 5, 1993
	6,372,920	Aug 16, 2002	Minaskanian, et al.	549/75	Nov 16, 2000
	Examiner's	Examiner's Initials Document Number 2003/0026830 2003/0027793 2003/0166709 2004/0034083 2004/0081683 2004/0137045 2004/0209861 2005/0032843 2005/0033065 2005/0079206 2005/0175678 2005/0260254 2006/0263419 2007/0072917 2007/0093546 2007/0191308 2007/0197480 2008/0138389 2008/0146622 2008/0274061 2009/0143460 5,177,112 5,382,596	Examiner's Initials         Document Number         Publication Date           2003/0026830         Feb 6, 2003           2003/0027793         Feb 6, 2003           2003/0166709         Sep 4, 2003           2004/0034083         Feb 19, 2004           2004/0048779         Mar 11, 2004           2004/0081683         Apr 29, 2004           2004/0209861         Oct 21, 2004           2005/0032843         Feb 10, 2005           2005/0033065         Feb 10, 2005           2005/0079206         Apr 14, 2005           2005/0260254         Nov 24, 2005           2006/0263419         Nov 23, 2006           2007/0072917         Mar 29, 2007           2007/0191308         Aug 16, 2007           2007/0197480         Aug 23, 2007           2008/0008748         Jan 10, 2008           2008/0138389         Jun 12, 2008           2008/0274061         Nov 6, 2008           2009/0143460         Jun 4, 2009           5,177,112         Jan 5, 1993           5,382,596         Jan 17, 1995	Examiner's Initials	Examiner's   Document Number   Publication Date   Name   Class/ Subclass

/Sahar Javanmard/ 05/07/2010 Examiner: Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./ FORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET No.	Serial No.		
6102-000048/US/NP	10/593,964		
APPLICANT			
Scheller, D., et al.			
FILING DATE	GROUP		
September 22, 206	1617		

U.S. P.	U.S. PATENT DOCUMENTS					
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		6,884,434	Apr 26, 2005	Muller, et al.	424/487	Nov 28, 2000
		7,309,497	Dec 18, 2007	Rimpler, et al.	424/422	Feb 11, 2003
		7,413,747	Aug 19, 2008	Mueller, et al.	424/448	Oct 31, 2007

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translati Yes	on No
		WO 02/31499	Apr 18, 2002	WIPO	G01N 33/53		

OTHER	OTHER DOCUMENTS				
Ref. Desig.	Examiner's Initials				
		Becker, et al. ( (2002) "Early diagnosis of Parkinson's disease." J Neurol 249(Suppl 3):III/40-III/48			
		Gerlach, et al. (2003) "Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease." Neurotoxicity Research 5(1):43-51			
		Guttman, et al. (2003) "Current concepts in the diagnosis and management on Parkinson's disease.' CMAJ, 168(3):293-301			
		Hughes, et al. (1992) "Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases." Journal of Neurology, Neurosurgery, and Psychiatry 55:181-184			
		Kihara, et al. (2002) "Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase casade." J. Neurosci. Res. 70:274-282			
		Martinez-Martin, <i>et al.</i> (1994) "Unified Parkinson's disease rating scale characteristics and structure." Movement Disorders 9(1):76-83			
		McKay, et al. (2008) "Will stem cell biology generate new therapies for Parkinson's disease?" Neuron 58:659-661			
		Nair, et al. (2003) "Activation of phosphoinositide 3-kinase by D <sub>2</sub> receptor prevents apoptosis in dopaminergic cell lines." Biochem. J. 373:25-32			
		Oertel, et al. (2003) "New aspects in the treatment of Parkinson's disease." Akt Neurol 30(Suppl 2):S263-265			

Examiner:	/Sahar Javanmard/	Date Considered:	05/07/2010
-----------	-------------------	------------------	------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## FORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 3

SERIAL NO.	
10/593,964	
GROUP	
1617	

OTHER	OTHER DOCUMENTS				
Ref. Desig.	Examiner's Initials				
		Oertel, et al. (2003) "New aspects in the treatment of Parkinson's disease." Akt Neurol 30(Suppl 2):S263-265 (English Translation)			
		R & D Focus Drugs News, 20 Aug 2001, "Drug delivery system, transdermal rotigotine Schwartz clinical data (treatment of Parkinson's disease." IMS World Pulications Ltd. ISSN:1350-1135			
		Schapira (2002) "Neuroprotection and dopamine agonists." Neurology 58(Suppl 1):S9-S18			
		Scheller, et al. (2007) "Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease." Experimental Neurology 203:415-422			
		Scheller, et al. (2008) "Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease." Neuroscience Letters 432:30-34			
		Sherman (2001) "Augmentation strategy aids treatment-resistant depression. (Dopamine Agonist).(pramipexole for mental depression)." Clinical Psychiatry News p.1-2			
		Shoulson, <i>et al.</i> (2003) "A controlled trial of rotigotine monotherapy in early Parkinson's disease." Arch. Neurol. 60:1721-1728			
		Takashima, <i>et al.</i> (1999) "Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D₂receptors." Exp. Neurol. 159:98-104			
		Thomas, et al. (2007) "Dopa-responsive pseudo-orthostatic tremor in Parkinsonism." Movement Disorders 22(11):1652-1656			
		Tuite, et al. (2003) "Recent developments in the pharmacological treatment of Parkinson's disease." Expert Opin. Investig. Drugs 12(8):1335-1352			
		Van der Weide, et al. (1988) "The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors." Eur J Pharmacol 146:319-326			

60615819.1

Examiner: /Sahar Javanmard/ Date Considered: 05/07/2010

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.